Melbourne School of Population and Global Health - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 10 of 45
  • Item
    Thumbnail Image
    DNA methylation-based biological aging and cancer risk and survival: Pooled analysis of seven prospective studies
    Dugue, P-A ; Bassett, JK ; Joo, JE ; Jung, C-H ; Wong, EM ; Moreno-Betancur, M ; Schmidt, D ; Makalic, E ; Li, S ; Severi, G ; Hodge, AM ; Buchanan, DD ; English, DR ; Hopper, JL ; Southey, MC ; Giles, GG ; Milne, RL (WILEY, 2018-04-15)
    The association between aging and cancer is complex. Recent studies have developed measures of biological aging based on DNA methylation and called them "age acceleration." We aimed to assess the associations of age acceleration with risk of and survival from seven common cancers. Seven case-control studies of DNA methylation and colorectal, gastric, kidney, lung, prostate and urothelial cancer and B-cell lymphoma nested in the Melbourne Collaborative Cohort Study were conducted. Cancer cases, vital status and cause of death were ascertained through linkage with cancer and death registries. Conditional logistic regression and Cox models were used to estimate odds ratios (OR) and hazard ratios (HR) and 95% confidence intervals (CI) for associations of five age acceleration measures derived from the Human Methylation 450 K Beadchip assay with cancer risk (N = 3,216 cases) and survival (N = 1,726 deaths), respectively. Epigenetic aging was associated with increased cancer risk, ranging from 4% to 9% per five-year age acceleration for the 5 measures considered. Heterogeneity by study was observed, with stronger associations for risk of kidney cancer and B-cell lymphoma. An associated increased risk of death following cancer diagnosis ranged from 2% to 6% per five-year age acceleration, with no evidence of heterogeneity by cancer site. Cancer risk and mortality were increased by 15-30% for the fourth versus first quartile of age acceleration. DNA methylation-based measures of biological aging are associated with increased cancer risk and shorter cancer survival, independently of major health risk factors.
  • Item
    Thumbnail Image
    Genome-Wide Measures of Peripheral Blood Dna Methylation and Prostate Cancer Risk in a Prospective Nested Case-Control Study
    FitzGerald, LM ; Naeem, H ; Makalic, E ; Schmidt, DF ; Dowty, JG ; Joo, JE ; Jung, C-H ; Bassett, JK ; Dugue, P-A ; Chung, J ; Lonie, A ; Milne, RL ; Wong, EM ; Hopper, JL ; English, DR ; Severi, G ; Baglietto, L ; Pedersen, J ; Giles, GG ; Southey, MC (WILEY, 2017-04-01)
  • Item
    Thumbnail Image
    Genome-wide association study of peripheral blood DNA methylation and conventional mammographic density measures
    Li, S ; Dugue, P-A ; Baglietto, L ; Severi, G ; Wong, EM ; Nguyen, TL ; Stone, J ; English, DR ; Southey, MC ; Giles, GG ; Hopper, JL ; Milne, RL (WILEY, 2019-10-01)
    Age- and body mass index (BMI)-adjusted mammographic density is one of the strongest breast cancer risk factors. DNA methylation is a molecular mechanism that could underlie inter-individual variation in mammographic density. We aimed to investigate the association between breast cancer risk-predicting mammographic density measures and blood DNA methylation. For 436 women from the Australian Mammographic Density Twins and Sisters Study and 591 women from the Melbourne Collaborative Cohort Study, mammographic density (dense area, nondense area and percentage dense area) defined by the conventional brightness threshold was measured using the CUMULUS software, and peripheral blood DNA methylation was measured using the HumanMethylation450 (HM450) BeadChip assay. Associations between DNA methylation at >400,000 sites and mammographic density measures adjusted for age and BMI were assessed within each cohort and pooled using fixed-effect meta-analysis. Associations with methylation at genetic loci known to be associated with mammographic density were also examined. We found no genome-wide significant (p < 10-7 ) association for any mammographic density measure from the meta-analysis, or from the cohort-specific analyses. None of the 299 methylation sites located at genetic loci associated with mammographic density was associated with any mammographic density measure after adjusting for multiple testing (all p > 0.05/299 = 1.7 × 10-4 ). In summary, our study did not find evidence for associations between blood DNA methylation, as measured by the HM450 assay, and conventional mammographic density measures that predict breast cancer risk.
  • Item
    Thumbnail Image
    Heritable methylation marks associated with breast and prostate cancer risk
    Dugue, P-A ; Dowty, JG ; Joo, JE ; Wong, EM ; Makalic, E ; Schmidt, DF ; English, DR ; Hopper, JL ; Pedersen, J ; Severi, G ; MacInnis, RJ ; Milne, RL ; Giles, GG ; Southey, MC (WILEY, 2018-09-15)
    BACKGROUND: DNA methylation can mimic the effects of germline mutations in cancer predisposition genes. Recently, we identified twenty-four heritable methylation marks associated with breast cancer risk. As breast and prostate cancer share genetic risk factors, including rare, high-risk mutations (eg, in BRCA2), we hypothesized that some of these heritable methylation marks might also be associated with the risk of prostate cancer. METHODS: We studied 869 incident prostate cancers (430 aggressive and 439 non-aggressive) and 869 matched controls nested within a prospective cohort study. DNA methylation was measured in pre-diagnostic blood samples using the Illumina Infinium HM450K BeadChip. Conditional logistic regression models, adjusted for prostate cancer risk factors and blood cell composition, were used to estimate odds ratios and 95% confidence intervals for the association between the 24 methylation marks and the risk of prostate cancer. RESULTS: Five methylation marks within the VTRNA2-1 promoter region (cg06536614, cg00124993, cg26328633, cg25340688, and cg26896946), and one in the body of CLGN (cg22901919) were associated with the risk of prostate cancer. In stratified analyses, the five VTRNA2-1 marks were associated with the risk of aggressive prostate cancer. CONCLUSIONS: This work highlights a potentially important new area of investigation for prostate cancer susceptibility and adds to our knowledge about shared risk factors for breast and prostate cancer.
  • Item
    Thumbnail Image
    Socioeconomic position, lifestyle habits and biomarkers of epigenetic aging: a multi-cohort analysis
    Fiorito, G ; McCrory, C ; Robinson, O ; Carmeli, C ; Rosales, CO ; Zhang, Y ; Colicino, E ; Dugue, P-A ; Artaud, F ; Mckay, GJ ; Jeong, A ; Mishra, PP ; Nost, TH ; Krogh, V ; Panico, S ; Sacerdote, C ; Tumino, R ; Palli, D ; Matullo, G ; Guarrera, S ; Gandini, M ; Bochud, M ; Dermitzakis, E ; Muka, T ; Schwartz, J ; Vokonas, PS ; Just, A ; Hodge, AM ; Giles, GG ; Southey, MC ; Hurme, MA ; Young, I ; McKnight, AJ ; Kunze, S ; Waldenberger, M ; Peters, A ; Schwettmann, L ; Lund, E ; Baccarelli, A ; Milne, RL ; Kenny, RA ; Elbaz, A ; Brenner, H ; Kee, F ; Voortman, T ; Probst-Hensch, N ; Lehtimaki, T ; Elliot, P ; Stringhini, S ; Vineis, P ; Polidoro, S ; Alberts, J ; Alenius, H ; Avendano, M ; Baltar, V ; Bartley, M ; Barros, H ; Bellone, M ; Berger, E ; Blane, D ; Bochud, M ; Candiani, G ; Carmeli, C ; Carra, L ; Castagne, R ; Chadeau-Hyam, M ; Cima, S ; Clavel-Chapelon, F ; Costa, G ; Courtin, E ; Delpierre, C ; D'Errico, A ; Manolis, ; Dermitzakis, ; Dugue, P-A ; Elovainio, M ; Elliott, P ; Fagherazzi, G ; Fiorito, G ; Fraga, S ; Gandini, M ; Gares, V ; Gerbouin-Rerolle, P ; Giles, G ; Goldberg, M ; Greco, D ; Guessous, I ; Haba-Rubio, J ; Heinzer, R ; Hodge, A ; Joost, S ; Karimi, M ; Kelly-Irving, M ; Kahonen, M ; Karisola, P ; Khenissi, L ; Kivimaki, M ; Krogh, V ; Laine, J ; Lang, T ; Laurent, A ; Layte, R ; Lepage, B ; Lorsch, D ; MacGuire, F ; Machell, G ; Mackenbach, J ; Marmot, M ; de Mestral, C ; McCrory, C ; Miller, C ; Milne, R ; Muennig, P ; Nusselder, W ; Panico, S ; Petrovic, D ; Lourdes, ; Pilapil, ; Polidoro, S ; Preisig, M ; Pulkki-Raback, L ; Raitakari, O ; Ribeiro, AI ; Ricceri, F ; Recalcati, P ; Reinhard, E ; Robinson, O ; Valverde, JR ; Saba, S ; Sacerdote, C ; Santegoets, F ; Satolli, R ; Simmons, T ; Severi, G ; Shipley, MJ ; Stringhini, S ; Tabak, A ; Terhi, V ; Tieulent, J ; Tumino, R ; Vaccarella, S ; Vigna-Taglianti, F ; Vineis, P ; Vollenweider, P ; Vuilleumier, N ; Zins, M (IMPACT JOURNALS LLC, 2019-04-15)
    Differences in health status by socioeconomic position (SEP) tend to be more evident at older ages, suggesting the involvement of a biological mechanism responsive to the accumulation of deleterious exposures across the lifespan. DNA methylation (DNAm) has been proposed as a biomarker of biological aging that conserves memory of endogenous and exogenous stress during life.We examined the association of education level, as an indicator of SEP, and lifestyle-related variables with four biomarkers of age-dependent DNAm dysregulation: the total number of stochastic epigenetic mutations (SEMs) and three epigenetic clocks (Horvath, Hannum and Levine), in 18 cohorts spanning 12 countries.The four biological aging biomarkers were associated with education and different sets of risk factors independently, and the magnitude of the effects differed depending on the biomarker and the predictor. On average, the effect of low education on epigenetic aging was comparable with those of other lifestyle-related risk factors (obesity, alcohol intake), with the exception of smoking, which had a significantly stronger effect.Our study shows that low education is an independent predictor of accelerated biological (epigenetic) aging and that epigenetic clocks appear to be good candidates for disentangling the biological pathways underlying social inequalities in healthy aging and longevity.
  • Item
    Thumbnail Image
    Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript
    Kote-Jarai, Z ; Al Olama, AA ; Leongamornlert, D ; Tymrakiewicz, M ; Saunders, E ; Guy, M ; Giles, GG ; Severi, G ; Southey, M ; Hopper, JL ; Sit, KC ; Harris, JM ; Batra, J ; Spurdle, AB ; Clements, JA ; Hamdy, F ; Neal, D ; Donovan, J ; Muir, K ; Pharoah, PDP ; Chanock, SJ ; Brown, N ; Benlloch, S ; Castro, E ; Mahmud, N ; O'Brien, L ; Hall, A ; Sawyer, E ; Wilkinson, R ; Easton, DF ; Eeles, RA (SPRINGER, 2011-06)
    Genome-wide association studies (GWAS) have identified more than 30 prostate cancer (PrCa) susceptibility loci. One of these (rs2735839) is located close to a plausible candidate susceptibility gene, KLK3, which encodes prostate-specific antigen (PSA). PSA is widely used as a biomarker for PrCa detection and disease monitoring. To refine the association between PrCa and variants in this region, we used genotyping data from a two-stage GWAS using samples from the UK and Australia, and the Cancer Genetic Markers of Susceptibility (CGEMS) study. Genotypes were imputed for 197 and 312 single nucleotide polymorphisms (SNPs) from HapMap2 and the 1000 Genome Project, respectively. The most significant association with PrCa was with a previously unidentified SNP, rs17632542 (combined P = 3.9 × 10(-22)). This association was confirmed by direct genotyping in three stages of the UK/Australian GWAS, involving 10,405 cases and 10,681 controls (combined P = 1.9 × 10(-34)). rs17632542 is also shown to be associated with PSA levels and it is a non-synonymous coding SNP (Ile179Thr) in KLK3. Using molecular dynamic simulation, we showed evidence that this variant has the potential to introduce alterations in the protein or affect RNA splicing. We propose that rs17632542 may directly influence PrCa risk.
  • Item
    No Preview Available
    Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma
    Cerhan, JR ; Berndt, SI ; Vijai, J ; Ghesquieres, H ; McKay, J ; Wang, SS ; Wang, Z ; Yeager, M ; Conde, L ; de Bakker, PIW ; Nieters, A ; Cox, D ; Burdett, L ; Monnereau, A ; Flowers, CR ; De Roos, AJ ; Brooks-Wilson, AR ; Lan, Q ; Severi, G ; Melbye, M ; Gu, J ; Jackson, RD ; Kane, E ; Teras, LR ; Purdue, MP ; Vajdic, CM ; Spinelli, JJ ; Giles, GG ; Albanes, D ; Kelly, RS ; Zucca, M ; Bertrand, KA ; Zeleniuch-Jacquotte, A ; Lawrence, C ; Hutchinson, A ; Zhi, D ; Habermann, TM ; Link, BK ; Novak, AJ ; Dogan, A ; Asmann, YW ; Liebow, M ; Thompson, CA ; Ansell, SM ; Witzig, TE ; Weiner, GJ ; Veron, AS ; Zelenika, D ; Tilly, H ; Haioun, C ; Molina, TJ ; Hjalgrim, H ; Glimelius, B ; Adami, H-O ; Bracci, PM ; Riby, J ; Smith, MT ; Holly, EA ; Cozen, W ; Hartge, P ; Morton, LM ; Severson, RK ; Tinker, LF ; North, KE ; Becker, N ; Benavente, Y ; Boffetta, P ; Brennan, P ; Foretova, L ; Maynadie, M ; Staines, A ; Lightfoot, T ; Crouch, S ; Smith, A ; Roman, E ; Diver, WR ; Offit, K ; Zelenetz, A ; Klein, RJ ; Villano, DJ ; Zheng, T ; Zhang, Y ; Holford, TR ; Kricker, A ; Turner, J ; Southey, MC ; Clavel, J ; Virtamo, J ; Weinstein, S ; Riboli, E ; Vineis, P ; Kaaks, R ; Trichopoulos, D ; Vermeulen, RCH ; Boeing, H ; Tjonneland, A ; Angelucci, E ; Di Lollo, S ; Rais, M ; Birmann, BM ; Laden, F ; Giovannucci, E ; Kraft, P ; Huang, J ; Ma, B ; Ye, Y ; Chiu, BCH ; Sampson, J ; Liang, L ; Park, J-H ; Chung, CC ; Weisenburger, DD ; Chatterjee, N ; Fraumeni, JF ; Slager, SL ; Wu, X ; de Sanjose, S ; Smedby, KE ; Salles, G ; Skibola, CF ; Rothman, N ; Chanock, SJ (NATURE PUBLISHING GROUP, 2014-11)
    Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma subtype and is clinically aggressive. To identify genetic susceptibility loci for DLBCL, we conducted a meta-analysis of 3 new genome-wide association studies (GWAS) and 1 previous scan, totaling 3,857 cases and 7,666 controls of European ancestry, with additional genotyping of 9 promising SNPs in 1,359 cases and 4,557 controls. In our multi-stage analysis, five independent SNPs in four loci achieved genome-wide significance marked by rs116446171 at 6p25.3 (EXOC2; P = 2.33 × 10(-21)), rs2523607 at 6p21.33 (HLA-B; P = 2.40 × 10(-10)), rs79480871 at 2p23.3 (NCOA1; P = 4.23 × 10(-8)) and two independent SNPs, rs13255292 and rs4733601, at 8q24.21 (PVT1; P = 9.98 × 10(-13) and 3.63 × 10(-11), respectively). These data provide substantial new evidence for genetic susceptibility to this B cell malignancy and point to pathways involved in immune recognition and immune function in the pathogenesis of DLBCL.
  • Item
    No Preview Available
    A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer
    Al Olama, AA ; Kote-Jarai, Z ; Berndt, SI ; Conti, DV ; Schumacher, F ; Han, Y ; Benlloch, S ; Hazelett, DJ ; Wang, Z ; Saunders, E ; Leongamornlert, D ; Lindstrom, S ; Jugurnauth-Little, S ; Dadaev, T ; Tymrakiewicz, M ; Stram, DO ; Rand, K ; Wan, P ; Stram, A ; Sheng, X ; Pooler, LC ; Park, K ; Xia, L ; Tyrer, J ; Kolonel, LN ; Le Marchand, L ; Hoover, RN ; Machiela, MJ ; Yeager, M ; Burdette, L ; Chung, CC ; Hutchinson, A ; Yu, K ; Goh, C ; Ahmed, M ; Govindasami, K ; Guy, M ; Tammela, TLJ ; Auvinen, A ; Wahlfors, T ; Schleutker, J ; Visakorpi, T ; Leinonen, KA ; Xu, J ; Aly, M ; Donovan, J ; Travis, RC ; Key, TJ ; Siddiq, A ; Canzian, F ; Khaw, K-T ; Takahashi, A ; Kubo, M ; Pharoah, P ; Pashayan, N ; Weischer, M ; Nordestgaard, BG ; Nielsen, SF ; Klarskov, P ; Roder, MA ; Iversen, P ; Thibodeau, SN ; McDonnell, SK ; Schaid, DJ ; Stanford, JL ; Kolb, S ; Holt, S ; Knudsen, B ; Coll, AH ; Gapstur, SM ; Diver, WR ; Stevens, VL ; Maier, C ; Luedeke, M ; Herkommer, K ; Rinckleb, AE ; Strom, SS ; Pettaway, C ; Yeboah, ED ; Tettey, Y ; Biritwum, RB ; Adjei, AA ; Tay, E ; Truelove, A ; Niwa, S ; Choklcalingam, AP ; Cannon-Albright, L ; Cybulski, C ; Wokolorczyk, D ; Kluzniak, W ; Park, J ; Sellers, T ; Lin, H-Y ; Isaacs, WB ; Partin, AW ; Brenner, H ; Dieffenbach, AK ; Stegmaier, C ; Chen, C ; Giovannucci, EL ; Ma, J ; Stampfer, M ; Penney, KL ; Mucci, L ; John, EM ; Ingles, SA ; Kittles, RA ; Murphy, AB ; Pandha, H ; Michael, A ; Kierzek, AM ; Blot, W ; Signorello, LB ; Zheng, W ; Albanes, D ; Virtamo, J ; Weinstein, S ; Nemesure, B ; Carpten, J ; Leske, C ; Wu, S-Y ; Hennis, A ; Kibel, AS ; Rybicki, BA ; Neslund-Dudas, C ; Hsing, AW ; Chu, L ; Goodman, PJ ; Klein, EA ; Zheng, SL ; Batra, J ; Clements, J ; Spurdle, A ; Teixeira, MR ; Paulo, P ; Maia, S ; Slavov, C ; Kaneva, R ; Mitev, V ; Witte, JS ; Casey, G ; Gillanders, EM ; Seminara, D ; Riboli, E ; Hamdy, FC ; Coetzee, GA ; Li, Q ; Freedman, ML ; Hunter, DJ ; Muir, K ; Gronberg, H ; Nea, DE ; Southey, M ; Giles, GG ; Severi, G ; Cook, MB ; Nakagawa, H ; Wiklund, F ; Kraft, P ; Chanock, SJ ; Henderson, BE ; Easton, DF ; Eeles, RA ; Haiman, CA (NATURE PUBLISHING GROUP, 2014-10)
    Genome-wide association studies (GWAS) have identified 76 variants associated with prostate cancer risk predominantly in populations of European ancestry. To identify additional susceptibility loci for this common cancer, we conducted a meta-analysis of > 10 million SNPs in 43,303 prostate cancer cases and 43,737 controls from studies in populations of European, African, Japanese and Latino ancestry. Twenty-three new susceptibility loci were identified at association P < 5 × 10(-8); 15 variants were identified among men of European ancestry, 7 were identified in multi-ancestry analyses and 1 was associated with early-onset prostate cancer. These 23 variants, in combination with known prostate cancer risk variants, explain 33% of the familial risk for this disease in European-ancestry populations. These findings provide new regions for investigation into the pathogenesis of prostate cancer and demonstrate the usefulness of combining ancestrally diverse populations to discover risk loci for disease.
  • Item
    No Preview Available
    GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer
    Pharoah, PDP ; Tsai, Y-Y ; Ramus, SJ ; Phelan, CM ; Goode, EL ; Lawrenson, K ; Buckley, M ; Fridley, BL ; Tyrer, JP ; Shen, H ; Weber, R ; Karevan, R ; Larson, MC ; Song, H ; Tessier, DC ; Bacot, F ; Vincent, D ; Cunningham, JM ; Dennis, J ; Dicks, E ; Aben, KK ; Anton-Culver, H ; Antonenkova, N ; Armasu, SM ; Baglietto, L ; Bandera, EV ; Beckmann, MW ; Birrer, MJ ; Bloom, G ; Bogdanova, N ; Brenton, JD ; Brinton, LA ; Brooks-Wilson, A ; Brown, R ; Butzow, R ; Campbell, I ; Carney, ME ; Carvalho, RS ; Chang-Claude, J ; Chen, YA ; Chen, Z ; Chow, W-H ; Cicek, MS ; Coetzee, G ; Cook, LS ; Cramer, DW ; Cybulski, C ; Dansonka-Mieszkowska, A ; Despierre, E ; Doherty, JA ; Doerk, T ; du Bois, A ; Duerst, M ; Eccles, D ; Edwards, R ; Ekici, AB ; Fasching, PA ; Fenstermacher, D ; Flanagan, J ; Gao, Y-T ; Garcia-Closas, M ; Gentry-Maharaj, A ; Giles, G ; Gjyshi, A ; Gore, M ; Gronwald, J ; Guo, Q ; Halle, MK ; Harter, P ; Hein, A ; Heitz, F ; Hillemanns, P ; Hoatlin, M ; Hogdall, E ; Hogdall, CK ; Hosono, S ; Jakubowska, A ; Jensen, A ; Kalli, KR ; Karlan, BY ; Kelemen, LE ; Kiemeney, LA ; Kjaer, SK ; Konecny, GE ; Krakstad, C ; Kupryjanczyk, J ; Lambrechts, D ; Lambrechts, S ; Le, ND ; Lee, N ; Lee, J ; Leminen, A ; Lim, BK ; Lissowska, J ; Lubinski, J ; Lundvall, L ; Lurie, G ; Massuger, LFAG ; Matsuo, K ; McGuire, V ; McLaughlin, JR ; Menon, U ; Modugno, F ; Moysich, KB ; Nakanishi, T ; Narod, SA ; Ness, RB ; Nevanlinna, H ; Nickels, S ; Noushmehr, H ; Odunsi, K ; Olson, S ; Orlow, I ; Paul, J ; Pejovic, T ; Pelttari, LM ; Permuth-Wey, J ; Pike, MC ; Poole, EM ; Qu, X ; Risch, HA ; Rodriguez-Rodriguez, L ; Rossing, MA ; Rudolph, A ; Runnebaum, I ; Rzepecka, IK ; Salvesen, HB ; Schwaab, I ; Severi, G ; Shen, H ; Shridhar, V ; Shu, X-O ; Sieh, W ; Southey, MC ; Spellman, P ; Tajima, K ; Teo, S-H ; Terry, KL ; Thompson, PJ ; Timorek, A ; Tworoger, SS ; van Altena, AM ; van den Berg, D ; Vergote, I ; Vierkant, RA ; Vitonis, AF ; Wang-Gohrke, S ; Wentzensen, N ; Whittemore, AS ; Wik, E ; Winterhoff, B ; Woo, YL ; Wu, AH ; Yang, HP ; Zheng, W ; Ziogas, A ; Zulkifli, F ; Goodman, MT ; Hall, P ; Easton, DF ; Pearce, CL ; Berchuck, A ; Chenevix-Trench, G ; Iversen, E ; Monteiro, ANA ; Gayther, SA ; Schildkraut, JM ; Sellers, TA (NATURE PUBLISHING GROUP, 2013-04)
    Genome-wide association studies (GWAS) have identified four susceptibility loci for epithelial ovarian cancer (EOC), with another two suggestive loci reaching near genome-wide significance. We pooled data from a GWAS conducted in North America with another GWAS from the UK. We selected the top 24,551 SNPs for inclusion on the iCOGS custom genotyping array. We performed follow-up genotyping in 18,174 individuals with EOC (cases) and 26,134 controls from 43 studies from the Ovarian Cancer Association Consortium. We validated the two loci at 3q25 and 17q21 that were previously found to have associations close to genome-wide significance and identified three loci newly associated with risk: two loci associated with all EOC subtypes at 8q21 (rs11782652, P = 5.5 × 10(-9)) and 10p12 (rs1243180, P = 1.8 × 10(-8)) and another locus specific to the serous subtype at 17q12 (rs757210, P = 8.1 × 10(-10)). An integrated molecular analysis of genes and regulatory regions at these loci provided evidence for functional mechanisms underlying susceptibility and implicated CHMP4C in the pathogenesis of ovarian cancer.
  • Item
    No Preview Available
    Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31
    Permuth-Wey, J ; Lawrenson, K ; Shen, HC ; Velkova, A ; Tyrer, JP ; Chen, Z ; Lin, H-Y ; Chen, YA ; Tsai, Y-Y ; Qu, X ; Ramus, SJ ; Karevan, R ; Lee, J ; Lee, N ; Larson, MC ; Aben, KK ; Anton-Culver, H ; Antonenkova, N ; Antoniou, AC ; Armasu, SM ; Bacot, F ; Baglietto, L ; Bandera, EV ; Barnholtz-Sloan, J ; Beckmann, MW ; Birrer, MJ ; Bloom, G ; Bogdanova, N ; Brinton, LA ; Brooks-Wilson, A ; Brown, R ; Butzow, R ; Cai, Q ; Campbell, I ; Chang-Claude, J ; Chanock, S ; Chenevix-Trench, G ; Cheng, JQ ; Cicek, MS ; Coetzee, GA ; Cook, LS ; Couch, FJ ; Cramer, DW ; Cunningham, JM ; Dansonka-Mieszkowska, A ; Despierre, E ; Doherty, JA ; Doerk, T ; du Bois, A ; Duerst, M ; Easton, DF ; Eccles, D ; Edwards, R ; Ekici, AB ; Fasching, PA ; Fenstermacher, DA ; Flanagan, JM ; Garcia-Closas, M ; Gentry-Maharaj, A ; Giles, GG ; Glasspool, RM ; Gonzalez-Bosquet, J ; Goodman, MT ; Gore, M ; Gorski, B ; Gronwald, J ; Hall, P ; Halle, MK ; Harter, P ; Heitz, F ; Hillemanns, P ; Hoatlin, M ; Hogdall, CK ; Hogdall, E ; Hosono, S ; Jakubowska, A ; Jensen, A ; Jim, H ; Kalli, KR ; Karlan, BY ; Kaye, SB ; Kelemen, LE ; Kiemeney, LA ; Kikkawa, F ; Konecny, GE ; Krakstad, C ; Kjaer, SK ; Kupryjanczyk, J ; Lambrechts, D ; Lambrechts, S ; Lancaster, JM ; Le, ND ; Leminen, A ; Levine, DA ; Liang, D ; Lim, BK ; Lin, J ; Lissowska, J ; Lu, KH ; Lubinski, J ; Lurie, G ; Massuger, LFAG ; Matsuo, K ; McGuire, V ; McLaughlin, JR ; Menon, U ; Modugno, F ; Moysich, KB ; Nakanishi, T ; Narod, SA ; Nedergaard, L ; Ness, RB ; Nevanlinna, H ; Nickels, S ; Noushmehr, H ; Odunsi, K ; Olson, SH ; Orlow, I ; Paul, J ; Pearce, CL ; Pejovic, T ; Pelttari, LM ; Pike, MC ; Poole, EM ; Raska, P ; Renner, SP ; Risch, HA ; Rodriguez-Rodriguez, L ; Rossing, MA ; Rudolph, A ; Runnebaum, IB ; Rzepecka, IK ; Salvesen, HB ; Schwaab, I ; Severi, G ; Shridhar, V ; Shu, X-O ; Shvetsov, YB ; Sieh, W ; Song, H ; Southey, MC ; Spiewankiewicz, B ; Stram, D ; Sutphen, R ; Teo, S-H ; Terry, KL ; Tessier, DC ; Thompson, PJ ; Tworoger, SS ; van Altena, AM ; Vergote, I ; Vierkant, RA ; Vincent, D ; Vitonis, AF ; Wang-Gohrke, S ; Weber, RP ; Wentzensen, N ; Whittemore, AS ; Wik, E ; Wilkens, LR ; Winterhoff, B ; Woo, YL ; Wu, AH ; Xiang, Y-B ; Yang, HP ; Zheng, W ; Ziogas, A ; Zulkifli, F ; Phelan, CM ; Iversen, E ; Schildkraut, JM ; Berchuck, A ; Fridley, BL ; Goode, EL ; Pharoah, PDP ; Monteiro, ANA ; Sellers, TA ; Gayther, SA (NATURE RESEARCH, 2013-03)
    Epithelial ovarian cancer (EOC) has a heritable component that remains to be fully characterized. Most identified common susceptibility variants lie in non-protein-coding sequences. We hypothesized that variants in the 3' untranslated region at putative microRNA (miRNA)-binding sites represent functional targets that influence EOC susceptibility. Here, we evaluate the association between 767 miRNA-related single-nucleotide polymorphisms (miRSNPs) and EOC risk in 18,174 EOC cases and 26,134 controls from 43 studies genotyped through the Collaborative Oncological Gene-environment Study. We identify several miRSNPs associated with invasive serous EOC risk (odds ratio=1.12, P=10(-8)) mapping to an inversion polymorphism at 17q21.31. Additional genotyping of non-miRSNPs at 17q21.31 reveals stronger signals outside the inversion (P=10(-10)). Variation at 17q21.31 is associated with neurological diseases, and our collaboration is the first to report an association with EOC susceptibility. An integrated molecular analysis in this region provides evidence for ARHGAP27 and PLEKHM1 as candidate EOC susceptibility genes.